XORTX Therapeutics (XRTX) - 2023 Q1 - Quarterly Report

Exhibit 99.1 CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS For the three months ended March 31, 2023 and 2022 (Unaudited - expressed in U.S. Dollars) XORTX THERAPEUTICS INC. Condensed Interim Consolidated Statements of Financial Position (Unaudited - expressed in U.S. Dollars) December 31, January 1, 2022 2022 March 31, Restated Restated Note 2023 (Note 2) (Note 2) $ $ Assets Current Cash and cash equivalents 5 7,908,461 10,434,196 14,869,861 Accounts receivable 36,421 81,752 40,654 Prepaid expenses 6 ...